Physiological Intra-Cytoplasmic Sperm Injection, also known as PICSI®, is a sperm selection device that assists the Embryologist in distinguishing the mature hyaluronan-binding sperm from immature non-binding sperm. PICSI® may be suggested when your reproductive specialist recommends ICSI (Intra-Cytoplasmic Sperm Injection) for your treatment in which an individual sperm is captured and injected into the egg to fertilize it. Without the PICSI device, sperm are selected for ICSI based on appearance and motility alone. Unexplained infertility or pregnancy loss can however be due to the fact that the sperm selected in the ICSI process was immature and had compromised DNA integrity. Therefore, using the PICSI device, the selected sperm not only have normal morphology and are motile, but their physiological ability to bind to hyaluronan has also been assessed resulting in selection of sperm that are more mature and have less DNA damage.

Sperm with benefits! A recent study compared hyaluronan-binding sperm to motile sperm in ICSI patients with low binding scores. Those who received the PICSI-selected sperm were more likely to get pregnant compared to their counterparts. More importantly, among the control (non-PICSI) patients, 15% of the pregnancies detected by the presence of a fetal sac never developed a fetal heart beat. Among the PICSI group, none of the pregnancies detected by the presence of a fetal sac were lost – all of them developed a fetal heart beat. The study explained the improved pregnancy rates by showing that the embryos created with hyaluronan-binding sperm exhibited greater viability. They had less fragmentation and better cell growth on day 3 and better blastocyst formation on day 5. A newer report from the Society of Assisted Reproductive Technology (SART) analyzed a large embryo morphology database and confirmed that the quality of the day 3 embryo relates directly to live birth rate; better quality embryos yield higher birth rates, and PICSI-derived embryos are higher quality. .

Patients Profile ;

  • 38 age groups
  • Patients with young but low ovarian reserve
  • Patients with sperm with DNA damage
  • Patient groups with 2 or more trials
  • In the previous trials, patient groups with no blastocyst on day 5
WhatsApp chat